{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:06:43Z","timestamp":1784221603308,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012781","name":"Merck Sharp and Dohme K.K.","doi-asserted-by":"publisher","award":["2014 00309042"],"award-info":[{"award-number":["2014 00309042"]}],"id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012781","name":"Merck Sharp and Dohme K.K.","doi-asserted-by":"publisher","award":["NCT02580994"],"award-info":[{"award-number":["NCT02580994"]}],"id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004897","name":"European Organisation for Research and Treatment of Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejca.2025.116059","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:36:57Z","timestamp":1761788217000},"page":"116059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["EORTC 1417 - REACTION: A phase II study of etoposide and cis\/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer"],"prefix":"10.1016","volume":"231","author":[{"given":"Jessica","family":"Menis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Greiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6399-3562","authenticated-orcid":false,"given":"Pierre","family":"Demontrond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3279-9569","authenticated-orcid":false,"given":"Isabelle","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-9074","authenticated-orcid":false,"given":"Robin","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Decroisette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-0729","authenticated-orcid":false,"given":"Nicolas","family":"Cloarec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Robinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7735-5366","authenticated-orcid":false,"given":"Roland","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8126-7019","authenticated-orcid":false,"given":"Jerome","family":"Fayette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-3650","authenticated-orcid":false,"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2611-5319","authenticated-orcid":false,"given":"Raffaele","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0872-2983","authenticated-orcid":false,"given":"Boris","family":"Duchemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Luciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Colantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassin","family":"Pretzenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1517-2510","authenticated-orcid":false,"given":"Caroline","family":"Caramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2538-7032","authenticated-orcid":false,"given":"Mario","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Berghmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bironzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Tugwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6938-4685","authenticated-orcid":false,"given":"Cong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-692X","authenticated-orcid":false,"given":"Steven","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-9957","authenticated-orcid":false,"given":"Karen","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Kilgour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Blackhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-8189","authenticated-orcid":false,"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116059_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.neo.2017.07.007","article-title":"What\u2019s new in SCLC? A review","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejca.2025.116059_bib2","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2025.116059_bib3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.29098","article-title":"Small cell lung cancer: where do we go from here?","volume":"121","author":"Byers","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.116059_bib4","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-14-2958","article-title":"Small cell lung cancer: will recent progress lead to improved outcomes?","volume":"21","author":"Pietanza","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2025.116059_bib5","doi-asserted-by":"crossref","first-page":"vi99","DOI":"10.1093\/annonc\/mdt178","article-title":"Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Fr\u00fch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116059_bib6","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","article-title":"Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline","volume":"33","author":"Rudin","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116059_bib7","unstructured":"Japan Lung Cancer Society. Lung cancer clinical practice guidelines 2018 version III. Small cell lung cancer (in Japanese). https:\/\/www. haigan.gr.jp\/guideline\/2018\/1\/3\/180103020100.html (accessed Aug 2, 2019)."},{"key":"10.1016\/j.ejca.2025.116059_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","article-title":"Current standards for clinical management of small cell lung cancer","volume":"7","author":"Farago","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2025.116059_bib9","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data","volume":"30","author":"Rossi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116059_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/srep15437","article-title":"Topotecan for relapsed small-cell lung cancer: systematic review and meta-analysis of 1347 patients","volume":"5","author":"Horita","year":"2015","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.ejca.2025.116059_bib11","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2025.116059_bib12","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.ejca.2025.116059_bib13","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116059_bib14","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2017.72.5069","article-title":"Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2025.116059_bib15","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"KEYNOTE-604 investigators. pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 Study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.116059_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0169-5002(02)00072-7","article-title":"Staging small cell lung cancer: veterans administration lung study group versus international association for the study of Lung Cancer--what limits limited disease?","volume":"37","author":"Micke","year":"2002","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2025.116059_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (Version1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116059_bib18","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","article-title":"Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system","volume":"13","author":"Riethdorf","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116059_bib19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cyto.b.20573","article-title":"External quality assurance of circulating tumor cell enumeration using the CellSearch((R)) system: a feasibility study","volume":"80","author":"Kraan","year":"2011","journal-title":"Cytom B Clin Cytom"},{"issue":"7","key":"10.1016\/j.ejca.2025.116059_bib20","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/annonc\/mdz122","article-title":"Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial","volume":"30","author":"Tay","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.116059_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1200\/JCO.2010.33.3716","article-title":"Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer","volume":"30","author":"Hou","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116059_bib22","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/S0022-5223(03)00707-4","article-title":"Cisplatin augments cytotoxic Tlymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer","volume":"126","author":"Merritt","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"10","key":"10.1016\/j.ejca.2025.116059_bib23","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/s43018-022-00415-9","article-title":"cfDNA methylome profiling for detection and subtyping of small cell lung cancers","volume":"3","author":"Chemi","year":"2022","journal-title":"Nat Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2025.116059_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2025.116059_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:23:10Z","timestamp":1773296590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925009451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"alternative-id":["S0959804925009451"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116059","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EORTC 1417 - REACTION: A phase II study of etoposide and cis\/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116059"}}